Home » Stocks » Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. (CNCE)

Stock Price: $9.08 USD -0.44 (-4.62%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 269.25M
Revenue (ttm) 79,000
Net Income (ttm) -76.82M
Shares Out 29.65M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $9.08
Previous Close $9.52
Change ($) -0.44
Change (%) -4.62%
Day's Open 9.50
Day's Range 8.94 - 9.50
Day's Volume 61,103
52-Week Range 5.36 - 13.09

More Stats

Market Cap 269.25M
Enterprise Value 121.29M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.65M
Float 22.61M
EPS (basic) -3.06
EPS (diluted) -3.06
FCF / Share -2.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 766,166
Short Ratio 5.10
Short % of Float 2.97%
Beta 0.91
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3,408.25
PB Ratio 1.66
Revenue 79,000
Operating Income -77.27M
Net Income -76.82M
Free Cash Flow -65.74M
Net Cash 147.96M
Net Cash / Share 4.99
Gross Margin -74,353.16%
Operating Margin -97,812.66%
Profit Margin -97,236.70%
FCF Margin -83,213.92%
ROA -26.06%
ROE -50.49%
ROIC -64.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$24.20*
(166.52% upside)
Low
18.0
Current: $9.08
High
30.0
Target: 24.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue1.0810.511440.1766.738.5825.4112.8519.47
Revenue Growth-89.75%-92.7%82595.98%-99.74%678.09%-66.25%97.74%-34%-
Gross Profit1.0810.511440.1766.738.5825.4112.8519.47
Operating Income-79.02-55.5892.65-51.1724.79-30.60-4.41-18.61-11.35
Net Income-78.17-56.0295.64-50.7224.17-31.70-6.06-20.44-11.32
Shares Outstanding23.7423.3722.6422.2321.1515.841.291.291.28
Earnings Per Share-3.29-2.404.06-2.281.09-2.00-4.99-16.15-9.66
Operating Cash Flow-48.76-48.03104-45.3423.06-29.7613.02-26.43-18.09
Capital Expenditures-0.69-2.87-0.95-0.77-0.87-0.80-0.36-0.47-0.29
Free Cash Flow-49.45-50.90103-46.1122.19-30.5612.66-26.90-18.38
Cash & Equivalents11316220596.5914379.6333.3828.2643.36
Total Debt16.00----7.1014.9219.737.14
Net Cash / Debt96.9716220596.5914372.5318.468.5336.23
Assets13719321210014784.4539.7733.1349.40
Liabilities36.0124.8115.3014.8016.3029.6339.6327.9724.66
Book Value10116819685.5913154.83-112-107-86.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Concert Pharmaceuticals, Inc.
Country United States
Employees 70
CEO Roger D. Tung

Stock Information

Ticker Symbol CNCE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CNCE
IPO Date February 13, 2014

Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.